Tyroserleutide TFA 可从猪脾脏的降解产物中分离得到,是一种小分子三肽,在体内外均可抑制肿瘤生长。
生物活性 |
Tyroserleutide TFA, isolated from the degradation products of porcine spleen[1], is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo[2].
|
IC50 Target |
Antitumor tripeptide[1][2]
|
体外研究 (In Vitro) |
Tyroserleutide (YSL) exhibits immuno-modulating effects, such as enhancing concanavalin (ConA) induced proliferation of mouse spleen lymphocytes, phagocytosis of mouse peritoneal macrophages, and the activity of natural killer (NK) cells[1]. Tyroserleutide (YSL), an immunologically therapeutic tripeptide, can promote hepatocarcinoma cell (H22) apoptosis through downregulating Bcl-2 and cyclin D1 expression[2]. Tyroserleutide is an ideal choice for inducing apoptosis of liver tumor cells[2]. Tyroserleutide inhibits tumor growth and does not cause severe toxicities in the major organs. Tyroserleutide can inhibit tumor cell migration[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
|
体内研究 (In Vivo) |
Tyroserleutide (10-80 μg/kg; injection (i.p.) one time every day until mice are dead) displays obvious anti-tumor activity. Tyroserleutide significantly prolongs the survival time of the murine H22 implanted mice[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: |
Female Kun-Ming mice (18-22 g, 6 week old) with H22 tumor model[1] |
Dosage: |
10, 20, 40, and 80 μg/kg |
Administration: |
Injection (i.p.) one time every day until mice were dead. |
Result: |
Survival times are 25.53±14.14, 25.82±14.29, 30.47±17.89, 35.06±20.90 days for 10, 20, 40, and 80 μg/kg, respectively. |
|
Clinical Trial |
|
分子量 |
|
Formula |
|
中文名称 |
|
运输条件 |
Room temperature in continental US; may vary elsewhere.
|
储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
Solvent Solubility |
In Vitro:;
H2O
Peptide Solubility and Storage Guidelines:
1.;;Calculate the length of the peptide.
2.;;Calculate the overall charge of the entire peptide according to the following table:
; |
Contents |
Assign value |
Acidic amino acid |
Asp (D), Glu (E), and the C-terminal -COOH. |
-1 |
Basic amino acid |
Arg (R), Lys (K), His (H), and the N-terminal -NH2 |
+1 |
Neutral amino acid |
Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) |
0 |
3.;;Recommended solution:
Overall charge of peptide |
Details |
Negative (lt;0) |
1.;;Try to dissolve the peptide in water first. 2.;;If water fails, add NH4OH (lt;50 μL). 3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide. |
Positive (gt;0) |
1.;;Try to dissolve the peptide in water first. 2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO. |
Zero (=0) |
1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration. |
|
参考文献 |
-
[1]. Wang C, et al. Studies on the large scale synthesis and anti-tumor activity of YSL. Prep Biochem Biotechnol. 2003 Aug;33(3):189-95.
[2]. Liang P, et al. pH-Triggered Conformational Change of Antp-Based Drug Delivery Platform for Tumor Treatment with Combined Photothermal Therapy and Chemotherapy. Adv Healthc Mater. 2019 Aug;8(15):e1900306.
|